232 related articles for article (PubMed ID: 1384643)
21. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide.
Creutzfeldt W; Bartsch HH; Jacubaschke U; Stöckmann F
Acta Oncol; 1991; 30(4):529-35. PubMed ID: 1713038
[TBL] [Abstract][Full Text] [Related]
22. Medical treatment of neuroendocrine gut and pancreatic tumors.
Oberg K; Eriksson B
Acta Oncol; 1989; 28(3):425-31. PubMed ID: 2472826
[TBL] [Abstract][Full Text] [Related]
23. A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours.
Hughes MJ; Kerr DJ; Cassidy J; Soukop M; McGregor K; Blackburn N; Yosef H; Kaye SB
Ann Oncol; 1996 Feb; 7(2):208-10. PubMed ID: 8777180
[TBL] [Abstract][Full Text] [Related]
24. Treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon.
Ahren B; Engman K; Lindblom A
Anticancer Res; 1992; 12(1):129-33. PubMed ID: 1567158
[TBL] [Abstract][Full Text] [Related]
25. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha.
Doberauer C; Mengelkoch B; Kloke O; Wandl U; Niederle N
Acta Oncol; 1991; 30(5):603-5. PubMed ID: 1892678
[TBL] [Abstract][Full Text] [Related]
26. Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors.
Zilembo N; Buzzoni R; Bajetta E; Di Bartolomeo M; de Braud F; Castellani R; Maffioli L; Celio L; Villa E; Lorusso V
Acta Oncol; 1993; 32(2):245-50. PubMed ID: 8391833
[TBL] [Abstract][Full Text] [Related]
27. [2 year interferon therapy of metastatic carcinoid tumor].
von Scheidt W; Böhm M; Huber I; Habersetzer R; Jacob K; Markl A; Autenrieth G
Klin Wochenschr; 1990 Feb; 68(4):241-6. PubMed ID: 2107357
[TBL] [Abstract][Full Text] [Related]
28. Recombinant alpha-2 interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours. A preliminary report.
Hanssen LE; Schrumpf E; Kolbenstvedt AN; Tausjø J; Dolva LO
Acta Oncol; 1989; 28(3):439-43. PubMed ID: 2742781
[TBL] [Abstract][Full Text] [Related]
29. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
Kölby L; Persson G; Franzén S; Ahrén B
Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
[TBL] [Abstract][Full Text] [Related]
30. Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group.
Neijt JP; Lacave AJ; Splinter TA; Taal BG; Veenhof CH; Sahmoud T; Lips CJ
Br J Cancer; 1995 Jan; 71(1):106-8. PubMed ID: 7819024
[TBL] [Abstract][Full Text] [Related]
31. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results.
Oberg K; Norheim I; Lind E; Alm G; Lundqvist G; Wide L; Jonsdottir B; Magnusson A; Wilander E
Cancer Treat Rep; 1986 Nov; 70(11):1297-304. PubMed ID: 2429764
[TBL] [Abstract][Full Text] [Related]
32. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin.
Kema IP; de Vries EG; Schellings AM; Postmus PE; Muskiet FA
Clin Chem; 1992 Apr; 38(4):534-40. PubMed ID: 1373675
[TBL] [Abstract][Full Text] [Related]
33. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer.
Willemse PH; de Vries EG; Mulder NH; Aalders JG; Bouma J; Sleijfer DT
Eur J Cancer; 1990 Mar; 26(3):353-8. PubMed ID: 2141493
[TBL] [Abstract][Full Text] [Related]
34. Carcinoid and neuroendocrine tumours of the liver.
Hodgson HJ; Maton PN
Baillieres Clin Gastroenterol; 1987 Jan; 1(1):35-61. PubMed ID: 3034360
[No Abstract] [Full Text] [Related]
35. [The application of 5-HT and 5-HIAA in the diagnosis of apudomas].
Xu SH; Chen YF; Chen HC
Zhonghua Nei Ke Za Zhi; 1990 Jul; 29(7):428-31, 446. PubMed ID: 1704304
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas.
Bashir S; Gibril F; Ojeaburu JV; Asgharian B; Entsuah LK; Ferraro G; Crafa P; Bordi C; Jensen RT
Aliment Pharmacol Ther; 2002 Jul; 16(7):1367-82. PubMed ID: 12144588
[TBL] [Abstract][Full Text] [Related]
37. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
38. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
39. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
40. Endocrine tumors of the pancreas associated with elevated urinary serotonin excretion.
Patchefsky AS; Gordon GS
Ann Clin Lab Sci; 1974; 4(5):383-93. PubMed ID: 4368678
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
